Australians with leiomyosarcoma or liposarcoma will now be able to access the novel anti-tumour agent Yondelis (trabectedin) at a cost of approximately $30 per script following its PBS listing in August 2023.
This will be of great financial benefit to patients who had previously had to around $44,000 per treatment.
Yondelis has demonstrated a 45% reduction in risk of disease progression or death compared to dacarbazine and has been available been available overseas since 2007. Accessing this drug at a reasonable price will be invaluable for the approximately 1600 Australians diagnosed with these cancers each year who may benefit from this treatment option.
Find out more
You can read the official press release here.